Swimmer plot of patient responses. Each line represents an individual patient. The solid green indicates the duration of ibrutinib therapy. Per protocol, ibrutinib was ceased in patients who were MRD-negative by flow cytometry at month 6 (when results of the test became available). Two patients (lanes 5 and 6) were MRD positive and continued ibrutinib beyond 6 months. The patient in lane 18 had an equivocal response assessment at month 4 after CTL019 infusion and continued ibrutinib until an early follow-up scan confirmed progressive disease (progression was deemed to have occurred at the earlier timepoint).